Effect of CYP2D6 Genotypes on the Metabolism of Haloperidol in a Japanese Psychiatric Population
Open Access
- 28 April 2003
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 28 (8) , 1501-1505
Abstract
We investigated the effect of CYP2D6 genotypes on plasma levels of haloperidol (HAL) and reduced haloperidol (RHAL) in 88 Japanese schizophrenic inpatients being treated with HAL. Some subjects carrying CYP2D6*5 allele (CYP2D6*1/CYP2D6*5, CYP2D6*5/CYP2D6*10) showed extremely high concentrations of both HAL and RHAL, and the groups with CYP2D6*5 allele seemed to have higher plasma concentrations of HAL (1.14±0.69 ng/ml/mg) and RHAL (1.10±1.05 ng/ml/mg) than the other groups. Among those without CYP2D6*5 allele, there were no significant differences in plasma concentrations of HAL and RHAL between those without CYP2D6*10 allele (HAL=0.68±0.31 ng/ml/mg, RHAL=0.28±0.37 ng/ml/mg), those with one CYP2D6*10 (HAL=0.70±0.23 ng/ml/mg, RHAL=0.31±0.16 ng/ml/mg) and those with two CYP2D6*10 alleles (HAL=0.69±0.14 ng/ml/mg, RHAL=0.40±0.09 ng/ml/mg), although there was a tendency of higher plasma concentration of RHAL in those with two CYP2D6*10 alleles. At a lower daily dosage of HAL (CYP2D6*10 allele(s) showed significantly higher plasma concentrations of RHAL (0.43±0.23 ng/ml/mg, 0.34±0.16 ng/ml/mg) than those without CYP2D6*10 allele (0.18±0.16 ng/ml/mg). The results of this study indicate that CYP2D6*10 allele plays significant but modest role in HAL metabolism in Japanese; nevertheless, we should not lump CYP2D6*10 allele with CYP2D6*5 allele because these two mutated alleles seem to have different impacts in the metabolism of HAL.Keywords
This publication has 23 references indexed in Scilit:
- Effects of the allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophreniaClinical Pharmacology & Therapeutics, 1999
- 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*Clinical Pharmacology & Therapeutics, 1998
- Polymorphic Drug OxidationCNS Drugs, 1996
- Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.Proceedings of the National Academy of Sciences, 1993
- Haloperidol Disposition Is Dependent on the Debrisoquine Hydroxylation PhenotypeTherapeutic Drug Monitoring, 1992
- Haloperidol Disposition Is Dependent on Debrisoquine Hydroxylation PhenotypeTherapeutic Drug Monitoring, 1992
- Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplificationThe Lancet, 1990
- Substantial rise in sparteine metabolic ratio during haloperidol treatment.British Journal of Clinical Pharmacology, 1989
- Determination of bromperidol in serum by automated column-switching high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1989
- Use of Antisera in the Isolation of Human Specific Conjugates of HaloperidolXenobiotica, 1989